+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Acute Heart Failure - Pipeline Review, H2 2015

  • ID: 3384505
  • Report
  • July 2015
  • 76 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Angion Biomedica Corp.
  • Bayer AG
  • Novartis AG
  • Nyken BV
  • Trevena, Inc.
  • MORE
‘Acute Heart Failure - Pipeline Review, H2 2015’, provides an overview of the Acute Heart Failure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Angion Biomedica Corp.
  • Bayer AG
  • Novartis AG
  • Nyken BV
  • Trevena, Inc.
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Acute Heart Failure Overview

Therapeutics Development

Pipeline Products for Acute Heart Failure - Overview

Pipeline Products for Acute Heart Failure - Comparative Analysis

Acute Heart Failure - Therapeutics under Development by Companies

Acute Heart Failure - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Acute Heart Failure - Products under Development by Companies

Acute Heart Failure - Companies Involved in Therapeutics Development

Amgen Inc.

Angion Biomedica Corp.

Bayer AG

Lee's Pharmaceutical Holdings Limited

Novartis AG

Nyken BV

Ono Pharmaceutical Co., Ltd.

PhaseBio Pharmaceuticals, Inc.

Trevena, Inc.

Acute Heart Failure - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ANG-4011 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BR-5489 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cenderitide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

istaroxime - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NYK-1112 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

omecamtiv mecarbil - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ONO-4232 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PB-1046 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

serelaxin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TRV-027 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TRV-120023 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ularitide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Acute Heart Failure - Recent Pipeline Updates

Acute Heart Failure - Dormant Projects

Acute Heart Failure - Discontinued Products

Acute Heart Failure - Product Development Milestones

Featured News & Press Releases

May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure

Mar 09, 2015: Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure

Feb 03, 2015: TRV027 Phase 2b BLAST-AHF Trial Design Published in Journal of the American College of Cardiology: Heart Failure

Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide

Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation

Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027

May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure

May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting

May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure

Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acute Heart Failure, H2 2015

Number of Products under Development for Acute Heart Failure - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Acute Heart Failure - Pipeline by Amgen Inc., H2 2015

Acute Heart Failure - Pipeline by Angion Biomedica Corp., H2 2015

Acute Heart Failure - Pipeline by Bayer AG, H2 2015

Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015

Acute Heart Failure - Pipeline by Novartis AG, H2 2015

Acute Heart Failure - Pipeline by Nyken BV, H2 2015

Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015

Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015

Acute Heart Failure - Pipeline by Trevena, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Acute Heart Failure Therapeutics - Recent Pipeline Updates, H2 2015

Acute Heart Failure - Dormant Projects, H2 2015

Acute Heart Failure - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Acute Heart Failure, H2 2015

Number of Products under Development for Acute Heart Failure - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
4 of 5
Amgen Inc.
Angion Biomedica Corp.
Bayer AG
Lee's Pharmaceutical Holdings Limited
Novartis AG
Nyken BV
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Trevena, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll